

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee Jul 2020 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
1	Blinatumomab	Blincyto	Malignant disease and immunosuppression	Approved	
2	Dexpanthenol eye gel	Corneregel	Eye	Approved	
3	Eltrombopag	Revolade	Nutrition and blood	Approved	
4	Eplerenone	Inspra	Cardiovascular system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
5	Ixekizumab	Taltz	Skin	Approved	
6	Letermovir	Prevymis	Infections	Approved	
7	Nivolumab / Ipilimumab	Opdivo / Yervoy	Malignant disease and immunosuppression	Approved	
8	Pertuzumab	Perjeta	Malignant disease and immunosuppression	Approved	
9	Racecadotril	Hidrasec	Gastro-intestinal system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
10	Rivaroxaban	Xarelto	Cardiovascular system	Approved	
11	Selexipag	Uptravi	Cardiovascular system	Approved	
12	Sodium hyaluronate eye drops	Hialid	Eye	Rejected	Alternative(s) available in HADF with comparable benefits
13	Tisagenlecleucel	Kymriah	Malignant disease and immunosuppression	Pending	Pending further information

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.